Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck announces acquisition of SmartCells

Merck announces acquisition of SmartCells

3rd December 2010

Merck has entered into a definitive agreement to purchase SmartCells, a company that produces a glucose-responsive insulin formulation for the treatment of diabetes mellitus.

In a statement published yesterday (December 2nd), Merck said it will acquire all outstanding stock in the company and provide SmartCells shareholders with an upfront cash payment.

They will also be eligible to receive development and regulatory milestones for products stemming from the transaction, with potential aggregate payments in excess of $500 million (320.2 million pounds).

Merck said the acquisition will equip its laboratories with innovative technology for the development of glucose-responsive insulins.

"If this investigational technology is ultimately approved for use with patients, it could provide an important new therapy for the treatment of diabetes," said Nancy Thornberry, senior vice-president and head of the company's diabetes and obesity franchise.

The acquisition was unanimously approved by the board of directors at SmartCells, which filed the patent for its SmartInsulin formulation in 2003. The company is based in Beverly, Massachusetts.ADNFCR-8000103-ID-800270756-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.